Table of Contents
In September 2012, Otipax, a common ear care product in France, was fully delisted from the official reimbursement list (listed at a 15% reimbursement rate until August 2012). This clearly confirms the ongoing impetus of the French authorities to continue de-reimbursement for benign ear care products, despite the arrival of the newly elected socialist government in May 2012, and in spite of political communication over a possible halt on the de-reimbursement spree. This was a de-reimbursement...
Euromonitor International's Ear Care in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
* Get a detailed picture of the Ear Care market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Use this report to: - Receive information concerning the dynamics and forecasts in the OTC drugs and dietary supplements market - Receive information pertaining to the major regional trends in the global ...
The U.S. insomnia market is projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021 In 2016, the cognitive behavioural therapy for insomnia ...
This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...